Linical Co Ltd
TSE:2183

Watchlist Manager
Linical Co Ltd Logo
Linical Co Ltd
TSE:2183
Watchlist
Price: 316 JPY -1.56% Market Closed
Market Cap: ¥7.8B

Wall Street
Price Targets

Price Targets Summary
Linical Co Ltd

There are no price targets for Linical Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Linical Co Ltd Competitors:
Price Targets
DREAMFOLKS
Dreamfolks Services Ltd
81% Upside
SAMG
Silvercrest Asset Management Group Inc
43% Upside
TES
Tesmec SpA
-12% Downside
TMO
Thermo Fisher Scientific Inc
33% Upside

Revenue
Forecast

10% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
10% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

For the last 13 years the compound annual growth rate for Linical Co Ltd's revenue is 10%. The projected CAGR for the next 2 years is 12%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Operating Income forecast
is not available for
Linical Co Ltd

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Linical Co Ltd's stock price target?
Not Available

Linical Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Linical Co Ltd's Revenue forecast?
Projected CAGR
12%

For the last 13 years the compound annual growth rate for Linical Co Ltd's revenue is 10%. The projected CAGR for the next 2 years is 12%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett